Main container

Studio di fase 2 randomizzato, in cieco, controllato con placebo, su INBRX-109 nel condrosarcoma convenzionale non resecabile o metastatico

Title
Studio di fase 2 randomizzato, in cieco, controllato con placebo, su INBRX-109 nel condrosarcoma convenzionale non resecabile o metastatico
Code
PH2 INBRX- 109 SA CS
Type
Sperimentale con farmaco
Start Year
2023
Status
In Corso

Principal Investigator

Documents and Videos attachament

You might also be interested in

Clinical Trial
A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors
Read more
Clinical Trial
Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors
Read more
Content updated
24/02/2023 14:46